Elucidating the mechanisms of Buyang Huanwu Decoction in treating chronic cerebral ischemia: a combined approach using network pharmacology, molecular docking, and in vivo validation

This study aimed to explore the potential mechanisms of Buyang Huanwu Decoction (BHD) in regulating the AKT/TP53 pathway and reducing inflammatory responses for the treatment of chronic cerebral ischemia (CCI) using UHPLC-QE-MS combined with network pharmacology, molecular docking techniques, and animal experiment validation.